Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel condensate-modulating mechanism of action for the treatment of Wnt-driven cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback